441 Spam-Free Article(s) Found
Symbol Name Last Close Mkt Cap DailyStocks'
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Tuesday’s Close
AZN Astrazeneca PLC $37.56 $95.16B N/A
Article Searches
Sanofi (SNY) Q1 Earnings Top, Genzyme & Vaccines Drive Sales http://www.zacks.com/stock/news/404335/sanofi-sny-q1-earnings-top-genzyme-vaccines-drive-sales?cid=CS-ZC-FT-404335 Apr 26, 2019 - Sanofi's first-quarter 2019 results were mixed as it beat estimates for earnings but missed the same for sales.
Bayer (BAYRY) Q1 Earnings Beat Estimates, Revenues Up Y/Y http://www.zacks.com/stock/news/403595/bayer-bayry-q1-earnings-beat-estimates-revenues-up-y-y?cid=CS-ZC-FT-403595 Apr 25, 2019 - Bayer (BAYRY) exceeds earnings estimates in the first quarter of 2019 and sales rise year over year.
What's in the Cards for AstraZeneca (AZN) in Q1 Earnings? http://www.zacks.com/stock/news/392203/whats-in-the-cards-for-astrazeneca-azn-in-q1-earnings?cid=CS-ZC-FT-392203 Apr 23, 2019 - AstraZeneca (AZN) will report first-quarter results on Apr 26. New drugs likely to drive sales.
AVEO Pharmaceuticals Down More Than 40% in 90 Days: Here's Why http://www.zacks.com/stock/news/386792/aveo-pharmaceuticals-down-more-than-40-in-90-days-heres-why?cid=CS-ZC-FT-386792 Apr 18, 2019 - AVEO Pharmaceuticals (AVEO) suffers a major hindrance as it defers its NDA filing for Fotivda in the United States.
Top Ranked Income Stocks to Buy for April 17th http://www.zacks.com/commentary/382754/top-ranked-income-stocks-to-buy-for-april-17th?cid=CS-ZC-FT-382754 Apr 17, 2019 - Top Ranked Income Stocks to Buy for April 17th
Clovis Stalls Mid-Stage Rubraca Study for Bladder Cancer http://www.zacks.com/stock/news/380655/clovis-stalls-mid-stage-rubraca-study-for-bladder-cancer?cid=CS-ZC-FT-380655 Apr 15, 2019 - Clovis Oncology (CLVS) halts mid-stage bladder cancer study evaluating Rubraca monotherapy. It is unlikely to provide meaningful clinical benefit as reviewed by an independent data monitoring committee.
Pharma Stock Roundup: AZN, MRK, GSK Get Regulatory Approvals, Sandoz Inks New Deal http://www.zacks.com/stock/news/379777/pharma-stock-roundup-azn-mrk-gsk-get-regulatory-approvals-sandoz-inks-new-deal?cid=CS-ZC-FT-379777 Apr 12, 2019 - Glaxo (GSK) gets FDA approval for a new HIV medicine, Dovato. AstraZeneca (AZN)/Merck's (MRK) Lynparza gets approval in EU for metastatic breast cancer.
Alkermes Reports Positive Data From Schizophrenia Study http://www.zacks.com/stock/news/377786/alkermes-reports-positive-data-from-schizophrenia-study?cid=CS-ZC-FT-377786 Apr 10, 2019 - Alkermes (ALKS) reports positive top-line data from phase IIIb study evaluating Aristada and Invega Sustenna in patients with acute exacerbations of schizophrenia.
AstraZeneca/Merck's Lynparza Wins EU Nod for Breast Cancer http://www.zacks.com/stock/news/377515/astrazeneca-mercks-lynparza-wins-eu-nod-for-breast-cancer?cid=CS-ZC-FT-377515 Apr 10, 2019 - AstraZeneca (AZN) and Merck gain an EU approval for Lynparza as a monotherapy for treating HER2-negative locally-advanced/metastatic breast cancer.
PhaseBio Stock Up on Breakthrough Therapy Status for PB2452 http://www.zacks.com/stock/news/375175/phasebio-stock-up-on-breakthrough-therapy-status-for-pb2452?cid=CS-ZC-FT-375175 Apr 09, 2019 - FDA grants PhaseBio's (PHAS) lead pipeline candidate, PB2452, Breakthrough Therapy status for treating bleeding risk associated with, AstraZeneca's antiplatelet drug Brilinta.

Pages: 12345678...45

<<<Page 3>